Overview
U.S. medical technology firm's fiscal Q2 revenue rose 5.2%, slightly beating analyst expectations
Adjusted EPS for fiscal Q2 rose 3.9% to $2.90, beating analyst expectations
Company executed $2.0 bln accelerated share repurchase and retired $2.1 bln of debt
Outlook
Company reaffirms full-year GAAP revenue growth guidance at low single-digit plus
Company expects full-year FX-neutral revenue growth at low single-digit
Becton Dickinson raises full-year adjusted diluted EPS guidance to $12.52-$12.72
Result Drivers
BROAD-BASED GROWTH - Over 90% of business delivered mid-single-digit revenue growth, according to CEO Tom Polen
MARGIN IMPROVEMENT - Ongoing margin momentum attributed to BD Excellence program, per management
INTERVENTIONAL SEGMENT STRENGTH - Interventional segment revenue rose 7.3% as reported, the fastest among major divisions
Company press release: ID:nPn49XYkDa
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Slight Beat*
$4.71 bln
$4.67 bln (12 Analysts)
Q2 Adjusted EPS
Beat
$2.90
$2.77 (12 Analysts)
Q2 EPS
-$0.13
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 10 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Becton Dickinson and Co is $194.00, about 34% above its May 6 closing price of $144.76
The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 11 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)